NBTX is trading 5.6% down at $37.25 in pre-market as the stock pulls back from overbought territory following a strong multi-day rally.

  • The move appears to be driven by normal volatility and profit-taking in the high-beta biotech name rather than a reaction to a clear catalyst.
  • No fresh company-specific news, earnings, or major filings were released overnight to account for the price action.